



## Zelda Therapeutics Broker/ Shareholders' Briefing Lunch Perth

**Dear Shareholders**  
**You are invited to a lunch briefing by**  
**Opthea CEO & MD Megan Baldwin &**  
**Zelda Therapeutics MD Richard Hopkins**

**12:15pm for 12:30pm 4 July 2019**  
**Mantra on Murray Hotel**  
**305 Murray St Perth**

### **Zelda Therapeutics (ASX: ZLD)**

- Global early mover into medicinal cannabis
- Autism, insomnia & opioid reduction studies underway with mid-year clinical outcomes
- Collaboration with world-leading Australian Telethon Kids Institute targeting paediatric brain cancer
- Strategic global distribution partnerships and leading experts combine through Zelda
- Global medicinal cannabis market worth \$12bn in 2018, forecast growth to \$40-55bn in 2028
- Market cap ~ \$31m

### **Opthea (ASX: OPT)**

- Developing new drug OPT-302 for the treatment of two serious eye diseases, wet AMD & DME, with multi-billion dollar market opportunity
- Clear evidence of clinical activity across multiple endpoints in Phase 2 wet AMD and Phase 1b DME trials
- Two large Phase 2 clinical trials underway at international trial sites, both readouts are expected 2H CY2019
- Strong cash position of \$25m as well as dominant shareholdings by US, European and Aust specialist institutional investors
- Market cap ~ \$157m

Limited spots: If you can attend please RSVP: [info@monsoon.com.au](mailto:info@monsoon.com.au) or call 03 9620 3333

---

*Copyright © 2018 Monsoon Communications, All rights reserved.*

**Our mailing address is:**

[info@monsoon.com.au](mailto:info@monsoon.com.au)

PH: 03 9620 3333